CGeneTech

CGeneTech is a Suzhou, China-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative small-molecule drugs. The company’s lead commercial product is sengliptin, a next-generation DPP-4 inhibitor for type 2 diabetes mellitus that has been approved for marketing in China under the brand name Shengjie Wei. Beyond metabolic disease, CGeneTech has built a broader pipeline spanning oncology, autoimmune disease, rare disease, and ophthalmology, including a CXCR4 antagonist and an FGFR/VEGFR dual inhibitor. The company presents itself as an integrated R&D organization with capabilities from lead discovery through clinical development, process research, and industrialization. It appears to be a private, active, commercial-stage biotech with recent financing activity and a quoted path toward capital markets.